Passage Bio, Inc. PASG
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -70.76%
- 1 year
- -53.38%
- Open
- 3.61
- Prev close
- 3.52
- Mkt cap
- 11.10M
- Vol
- 7.17K
- Avg vol
- 19.75K
- EPS
- -11.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.45
- High
- 3.61
- Forward P/E
- -1.30
- Beta
- 1.20
- Short ratio
- 6.61
- Inst. own
- 59.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.6579
- 200-d avg
- 0.93243
- 1y target
- 8.00
News
5 days ago globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Investigation for the Merger — BWMN, UTZ , PASG and FNWD
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders…
6 days ago gurufocus.com
MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWD
MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWDPR NewswireNEW YORK, Oct. 25, 2026NEW YORK, Oct. 25, 20
1 week ago gurufocus.com
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Passage Bio, Inc. (NASDAQ: PASG) and Remix Therapeutics, Inc. Upon closing of the
1 week ago businesswire.com
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Passage Bio, Inc. (NASDAQ: PASG) and Remix Therapeutics, Inc. Upon closing of the proposed…
1 week ago globenewswire.com
$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and…
2 weeks ago defenseworld.net
Passage Bio, Inc. (NASDAQ:PASG) Stock Has Average Price Target of $13.25 According to Brokerages
Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have earned a consensus rating of "Hold" from the nine ratings firms that are covering the company, MarketBeat reports. One investment…
3 weeks ago defenseworld.net
Passage Bio (NASDAQ:PASG) Stock Falls 2.4% – Here’s What Happened
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) shares traded down 2.4% during mid-day trading on Friday. The stock traded as low as $3.61 and last traded at $3.69. Approximately 12,111 shares…
1 month ago defenseworld.net
Analysts Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $13.25
Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have been assigned an average rating of "Hold" from the nine research firms that are currently covering the company, Marketbeat reports.…
-
2 months ago benzinga.com
Passage Bio Q2 EPS $(2.44) Beats $(3.47) Estimate
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(3.47) by 29.68 percent. This is a 17.57 percent increase over losses of $(2.96)…
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne…
4 months ago seekingalpha.com
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
-
4 months ago benzinga.com
9 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…
-
4 months ago benzinga.com
Passage Bio, Remix Therapeutics Sign All-Stock Business Combination Agreement; Combined Entity To Operate Under Remix Therapeutics, RMTX Ticker On Nasdaq
Passage Bio, Inc. (Nasdaq: PASG) ("Passage Bio") and Remix Therapeutics, Inc. ("Remix"), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and…
4 months ago globenewswire.com
Passage Bio and Remix Therapeutics Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin
-
6 months ago benzinga.com
Chardan Capital Downgrades Passage Bio to Neutral, Lowers Price Target to $7
Chardan Capital analyst Janani Sundararajan downgrades Passage Bio (NASDAQ:PASG) from Buy to Neutral and lowers the price target from $21 to $7.
6 months ago benzinga.com
This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday
Wall Street analysts changed outlook for top names, including downgrading Mohawk Industries and Passage Bio. See analyst ratings for these stocks.
-
6 months ago benzinga.com
Oppenheimer Maintains Outperform on Passage Bio, Lowers Price Target to $15
Oppenheimer analyst Jay Olson maintains Passage Bio (NASDAQ:PASG) with a Outperform and lowers the price target from $30 to $15.
-
6 months ago benzinga.com
Wedbush Downgrades Passage Bio to Neutral, Lowers Price Target to $8
Wedbush analyst Yun Zhong downgrades Passage Bio (NASDAQ:PASG) from Outperform to Neutral and lowers the price target from $32 to $8.
6 months ago benzinga.com
Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings
US stocks down at midday, Dow down 0.2%, NASDAQ down 0.52%. Energy up 1.1%, consumer discretionary down 1.2%. Investar beats earnings.
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
6 months ago benzinga.com
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results
US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric Biosciences, Fitness Champs, Clearmind Medicine surge.
-
6 months ago benzinga.com
Reported Earlier: Passage Bio Receives FDA Guidance Requiring Randomized Registrational Trial For PBFT02 in FTD-GRN, Evaluates Next Steps In Clinical Development
Regulatory & Program UpdateThe Company has completed a Type C meeting with the FDA to seek guidance on key elements of a future registrational trial of PBFT02 for FTD-GRN patients. Based on the…
-
6 months ago benzinga.com
Reported Earlier: Passage Bio Initiates Strategic Review, Exploring Mergers, Acquisitions, Partnerships, And Other Options To Maximize Shareholder Value
Corporate UpdateThe Company has initiated a review of strategic alternatives to maximize shareholder value. These strategic alternatives may include merger or acquisition transactions, a reverse…
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
6 months ago benzinga.com
Passage Bio Reports Updated Data From Ongoing Phase 1/2 upliFT-D Clinical Trial Evaluating PBFT02 For Treatment Of Frontotemporal Dementia With Granulin Mutations
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels FDA feedback from recent…
6 months ago globenewswire.com
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
7 months ago benzinga.com
Oppenheimer Initiates Coverage On Passage Bio with Outperform Rating, Announces Price Target of $30
Oppenheimer analyst Jay Olson initiates coverage on Passage Bio (NASDAQ:PASG) with a Outperform rating and announces Price Target of $30.
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
8 months ago defenseworld.net
Analysts Set Passage Bio, Inc. (NASDAQ:PASG) PT at $42.67
Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the four ratings firms that are currently covering the stock, MarketBeat…
-
8 months ago benzinga.com
Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $23
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $67 to $23.
-
8 months ago benzinga.com
Passage Bio Q4 EPS $(4.09) Misses $(2.68) Estimate
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(4.09) per share which missed the analyst consensus estimate of $(2.68) by 52.5 percent. This is a 2.25 percent decrease over losses of $(4.00)…
8 months ago globenewswire.com
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim…
8 months ago globenewswire.com
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative…
8 months ago defenseworld.net
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four brokerages that are currently covering the stock, MarketBeat reports. One…
9 months ago defenseworld.net
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $42.67
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been given an average rating of "Moderate Buy" by the four research firms that are currently covering the company, Marketbeat Ratings reports.…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
10 months ago defenseworld.net
Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)
Passage Bio (NASDAQ: PASG - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two…
10 months ago defenseworld.net
Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)
Passage Bio (NASDAQ: PASG - Get Free Report) and PepGen (NASDAQ: PEPG - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based…
11 months ago defenseworld.net
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four ratings firms that are covering the firm, Marketbeat Ratings reports. One…
-
11 months ago benzinga.com
Chardan Capital Maintains Buy on Passage Bio, Raises Price Target to $21
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and raises the price target from $6 to $21.
-
11 months ago benzinga.com
Passage Bio Q3 EPS $(2.44) Beats $(2.80) Estimate
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.80) by 12.86 percent. This is a 60.33 percent increase over losses of $(6.15)…
11 months ago globenewswire.com
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish…
-
1 year ago benzinga.com
Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $67
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $260 to $67.
-
1 year ago benzinga.com
Guggenheim Maintains Buy on Passage Bio, Lowers Price Target to $10
Guggenheim analyst Debjit Chattopadhyay maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $40 to $10.
-
1 year ago benzinga.com
Wedbush Maintains Outperform on Passage Bio, Raises Price Target to $40
Wedbush analyst Yun Zhong maintains Passage Bio (NASDAQ:PASG) with a Outperform and raises the price target from $3 to $40.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
Passage Bio Q2 EPS $(2.96) Misses $(0.21) Estimate
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.96) per share which missed the analyst consensus estimate of $(0.21) by 1309.52 percent. This is a 41.85 percent increase over losses of…